

Wessex Regional Genetics Laboratory Publications 2022

Blakes AJM, Wai HA, Davies I, Moledina HE, Ruiz A, Thomas T, **Bunyan D, Thomas NS,**

E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. 2022. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. *Leukemia* **36** (7): 1703-1719 [PMID: 35732831].

Lafferty N, **Salmon M**, **Cross NCP**, Singer I, Cooney A, Jayaprakash R. 2022. Chronic eosinophilic leukaemia associated with *JAK2* exon 13 insertion/deletion mutations. *Acta Haematol.* **145** (2): 201-206 [PMID: 34515041].

Lin S, Sanchez-Bretaña A, Leslie JS, Williams KB, Lee H, **Thomas NS**, **Callaway J**, Deline J, Arjuna Ratnayaka J, Baralle D, Schmitt MA, Norman CS, Hammond S, Harlalka GV, Ennis S, Cross HE, Wenger O, Crosby AH, Baple EL, Self JE. 2022. Evidence that the Ser192Tyr/Arg402Gln *in cis* Tyrosinase gene haplotype is a disease-causing allele in oculocutaneous albinism type 1B (OCA1B). *Genomic Medicine* **7** (1): 2 [PMID: 35027574].

Loong L, Cubuk C, Choi S, Allen S, Torr B, Garrett A, Loveday C, Durkie M, **Callaway A**, Burghel GJ, Drummond J, Robinson R, Berry IR, Wallace A, Eccles DM, Tischkowitz M, Ellard S, Ware JS, Hanson H, Turnbull C; on behalf of CanVIG-UK. 2022. Quantifying prediction of pathogenicity for within-codon concordance (PM5) using 7541 functional classifications of *BRCA1* and *MSH2* missense variants. *Genet. Med.* **24** (3): 552-563. [PMID: 34906453]

Loong L, Garrett A, Allen S, Choi S, Durkie M, **Callaway A**, Drummond J, Burghel GJ, Robinson R, Torr B, Berry IR, Wallace AJ, Eccles DM, Ellard S, Baple E, Evans DG, Woodward ER, Kulkarni A, Laloo F, Tischkowitz M, Lucassen A, Hanson H, Turnbull C; on behalf of the CanVIG-UK. 2022. Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK). *Genet. Med.* **24** (9): 1867-1877.

Lübke J, Schwaab J, Naumann N, Horny H-P, Weiß C, Metzgeroth G, Kreil S, **Cross NCP**, Sotlar K, Fabarius A, Hofmann W-K, Valent P, Gotlib J, Jawhar M, Reiter A. 2022. Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: a registry-based analysis. *J. Clin. Oncol.* **40** (16): 1783-1794.

Mackay D, Blik J, Kagami M, Tenorio-Castano J, Pereda A, Brioude F, Netchine I, Papingi D, de Franco E, **Lever M**, **Sillibourne J**, Lombardi P, Gaston V, Tauber M, Diene G, Bieth E, Fernandez L, Nevado J, Tümer Z, Riccio A, Maher ER, Beygo J, Tannorella P, Russo S, Perez de Nanclares G, Temple IK, Ogata T, Iqbal Z, et al. 2022. Progress towards a consensus strategy for multi-locus diagnostic testing of imprinting disorders. *Clin. Epigenetics* **14**: 143 [PMID: 36345041].

Moyo TK, Mendler JH, Itzykson R, Kishtagari A,

Salmon M, White HE, Zizkova H, Gottschalk A, Motlova E, Cerveira N, Colomer D, Coriu D, Franke GN, Gottardi E, Izzo B, Jurcek T, Lion T, Schäfer V, Venturi C, Vigneri P, Zawada M, Zuna J, Hovorkova L, Koblihova J, Klamova H, Stastna Markova M, Srbova D, Benesova A, Polivkova V, Zackova D, Mayer J, Roeder I, Glauche I, Ernst T, Hochhaus A, Machova Polakova K, **Cross NCP**. 2022. Impact of *BCR::ABL1* transcript type on RT-qPCR amplification performance and molecular response to therapy. *Leukemia* **36**: 1879-1886.

White HE, Salmon M, Albano F, Andersen CSA, Balabanov S, Balatzenko G, Barbany G, Cayuela J-M, Cerveira N, Cochaux P, Colomer D, Coriu D, Diamond J, Dietz C, Dulucq S, Engvall M, Franke GN, Gineikiene-Valentine E, Gniot M, Gómez-Casares MT, Gottardi E, Hayden C, Hayette S, Hedblom A, Ilea A, Izzo B, Jiménez-Velasco A, Jurcek T, Kairisto V, ihok L, Mitterbauer-Hohendanner G, Moeckel S, Naumann N, Nibourel O, Oppliger Leibundgut E, Panayiotidis P, Podgornik H, Pott C, Rapado I, Rose SJ, Schäfer V, Touloumenidou T, Veigaarmtrau5 g0 GM223(ne4(r)] TJETQq0.00000